$1.77
-0.05-2.75%
At Close: -
$1.90
0.137.29%
After Hours: 8:47 AM EDT
15 minutes delayed
Cognition Therapeutics
CGTXNASDAQ
Cognition Therapeutics (NASDAQ:CGTX) Stock, Analyst Ratings, Price Targets, Predictions
Cognition Therapeutics Inc has a consensus price target of $9.57, established from looking at the 11 latest analyst ratings. The last 3 analyst ratings were released from Rodman & Renshaw, Chardan Capital, and HC Wainwright & Co. on July 2, 2024, June 6, 2024, and May 29, 2024. With an average price target of $11.67 between Rodman & Renshaw, Chardan Capital, and HC Wainwright & Co., there's an implied 514.36% upside for Cognition Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Rodman & Renshaw
Chardan Capital
HC Wainwright & Co.
B. Riley Securities
Oppenheimer
1calculated from analyst ratings
Analyst Ratings for Cognition Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/02/2024 | Buy Now | 637.23% | Rodman & Renshaw | Elemer Piros | $14 → $14 | Reiterates | Buy → Buy | Get Alert |
| 06/06/2024 | Buy Now | 479.25% | Chardan Capital | Daniil Gataulin | → $11 | Initiates | → Buy | Get Alert |
| 05/29/2024 | Buy Now | 426.59% | HC Wainwright & Co. | Raghuram Selvaraju | → $10 | Initiates | → Buy | Get Alert |
| 03/28/2024 | Buy Now | 163.3% | B. Riley Securities | Mayank Mamtani | → $5 | Reiterates | Buy → Buy | Get Alert |
| 03/27/2024 | Buy Now | 373.93% | Oppenheimer | Jay Olson | $9 → $9 | Maintains | Outperform | Get Alert |
| 08/14/2023 | Buy Now | 215.96% | Ladenburg Thalmann | Aydin Huseynov | $10 → $6 | Maintains | Buy | Get Alert |
| 05/09/2023 | Buy Now | 373.93% | Oppenheimer | Jay Olson | → $9 | Reiterates | → Outperform | Get Alert |
| 03/24/2023 | Buy Now | 373.93% | Oppenheimer | Jay Olson | → $9 | Reiterates | → Outperform | Get Alert |
| 09/29/2022 | Buy Now | 531.91% | Cantor Fitzgerald | Charles Duncan | → $12 | Initiates | → Overweight | Get Alert |
| 04/22/2022 | Buy Now | 426.59% | Ladenburg Thalmann | Aydin Huseynov | → $10 | Initiates | → Buy | Get Alert |
| 11/03/2021 | Buy Now | 1058.5% | Oppenheimer | Jay Olson | — | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for Cognition Therapeutics (CGTX) stock?
The latest price target for Cognition Therapeutics (NASDAQ:CGTX) was reported by Rodman & Renshaw on July 2, 2024. The analyst firm set a price target for $14.00 expecting CGTX to rise to within 12 months (a possible 637.23% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cognition Therapeutics (CGTX)?
The latest analyst rating for Cognition Therapeutics (NASDAQ:CGTX) was provided by Rodman & Renshaw, and Cognition Therapeutics reiterated their buy rating.
When was the last upgrade for Cognition Therapeutics (CGTX)?
There is no last upgrade for Cognition Therapeutics
When was the last downgrade for Cognition Therapeutics (CGTX)?
There is no last downgrade for Cognition Therapeutics.
When is the next analyst rating going to be posted or updated for Cognition Therapeutics (CGTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cognition Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cognition Therapeutics was filed on July 2, 2024 so you should expect the next rating to be made available sometime around July 2, 2025.
Is the Analyst Rating Cognition Therapeutics (CGTX) correct?
While ratings are subjective and will change, the latest Cognition Therapeutics (CGTX) rating was a reiterated with a price target of $14.00 to $14.00. The current price Cognition Therapeutics (CGTX) is trading at is $1.90, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.